What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 243347.png

Kesimpta™

 

Indication: KESIMPTA™ is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS).

PI
BSS

ASCLEPIOS I & II Study Design

 

Watch a brief overview of the pivotal ASCLEPIOS trial results hosted by lead investigator, Professor Stephen Hauser

KESIMPTA vs other B cel therapies

 

Watch a brief overview on Kesimpta (Ofatumumab) vs other B cell therapies hosted by lead investigator, Professor Stephen Hause

Administration & Safety profile of Kesimpta (Ofatumumab)

 

Watch a brief overview on Kesimpta (Ofatumumab) Administration & Safety profile hosted by lead investigator, Professor Stephen Hauser

ARR, annual relapse rate; CDW, confirmed disability worsening; Gd+, gadolinium-enhancing; RMS, relapsing multiple sclerosis; NEDA, no evidence of disease activity.

KESIMPTA™ API

PDF
View